Biofrontera Inc. (BFRI): Price and Financial Metrics
GET POWR RATINGS... FREE!
BFRI Stock Price Chart Interactive Chart >
BFRI Price/Volume Stats
|Current price||$1.80||52-week high||$14.63|
|Prev. close||$1.86||52-week low||$1.77|
|Day high||$1.94||Avg. volume||1,969,498|
|50-day MA||$2.77||Dividend yield||N/A|
|200-day MA||$0.00||Market Cap||34.12M|
Biofrontera Inc. (BFRI) Company Bio
Biofrontera Inc., a biopharmaceutical company, develops and provides dermatological products for the treatment of skin diseases in the United States. It primarily develops therapies for non-melanoma skin cancer. It offers Ameluz, an aminolevulinic acid hydrochloride gel for the photodynamic therapy of actinic keratoses; and BF-RhodoLED, an LED lamp emitting red light for use in photodynamic therapy. The company was founded in 1997 and is based in Woburn, Massachusetts.
Most Popular Stories View All
BFRI Latest News Stream
|Loading, please wait...|
BFRI Latest Social Stream
View Full BFRI Social Stream
Latest BFRI News From Around the Web
Below are the latest news stories about Biofrontera Inc that investors may wish to consider to help them evaluate BFRI as an investment opportunity.
Good morning, trader!
Rise and shine, trader!
Biofrontera Inc. provides Update on Patient Recruitment for Phase III Study for the Treatment of sBCC with Ameluz®-PDT
WOBURN, Mass., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, is pleased to provide an update on the patient recruitment for the phase III clinical study for the treatment of superficial basal cell carcinoma (sBCC) with Ameluz® photodynamic therapy (Ameluz®-PDT) in combination with the BF-RhodoLED® lamp in the U.S. To date, 70% of the planned 186 patients have been en
Biofrontera Inc. Issues Letter to Shareholders Highlighting 2021 Successes and Key Elements of the Strategic Plan for 2022 and Beyond
WOBURN, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, today issued the following letter from CEO Erica Monaco and Executive Chairman of the Board Hermann Lübbert. To our valued stockholders, We would like to extend warm wishes to all of you for a healthy and prosperous 2022. At Biofrontera Inc., we welcomed the New Year with optimism and continued business mom
WOBURN, Mass., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced preliminary, unaudited revenue for the quarter and full year ended December 31, 2021. Revenue for the fourth quarter of 2021 is anticipated to be in the range of approximately $9.1 million to $9.2 million, an increase of approximately 7% over the same quarter last year. Revenue for the full
BFRI Price Returns